SCLN's EARNINGS CALL TRANSCRIPT and why it FELL today
Friedhelm Blobel - Chief Executive Officer, President and Director
Over the next few minutes, I will discuss why we believe that the enhancements and changes we are implementing should have a long-term positive effect in our business and reestablish our company on a sustainable growth trajectory.
First, I'll provide some background. The acquisition of NovaMed was a major strategic event that transformed our company and established SciClone as a substantial specialty pharmaceutical company in the China market with broad market presence and significant growth prospects. Almost overnight, SciClone grew from a small, essentially one-product company to midsize market competitor. We expanded our commercial, regulatory and reimbursement capabilities. We acquired a larger and therapeutically diverse portfolio of branded marketed products that span high-growth areas including infectious disease, cardiovascular disease, CNS disorders and oncology and added it to our flagship brand, ZADAXIN. We acquired a portfolio of potentially market-leading products still early in their life cycle, such as Aggrastat, and the development portfolio to drive long-term future growth. And we gained licensing and promotion collaboration with companies seeking to leverage our capabilities in the China market.
Post acquisition, we moved quickly and efficiently to put together management and commercial teams, align our regulatory strategies and support our business development and alliance management efforts. We reorganized and structured the existing sales teams and the commercial function. We upgraded our analytics, customer targeting and market intelligence tools. We executed on the marketing and regulatory strategies that were already in place and working at both companies, focusing on accelerating the forward momentum of the combined company so that we could achieve aggressive growth targets.
At the same time, we launched an extensive company-wide compliance effort and work diligently to put stronger, more comprehensive legal and compliance practices in place and promulgate those for intensive education and training throughout the organization. We believe that these efforts were appropriate and necessary. We delivered an impressive full year 2011 performance, including growing our flagship product, ZADAXIN, into $100 million plus brand. In 2012, our performance has been limited by the underperformance of NovaMed assets and the slow growth of the ZADAXIN brand. Nevertheless,....
READ THE FULL TRANSCRIPT AT SEEKINAPLHA. ITS A LONG ONE
I cant get it linked in here with the blocks
Just google "SciClone Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript". First link at the top from Seeking Alpha